Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Arecor Therapeutics plc (AREC.L)
Little Chesterford, GB
Arecor Therapeutics PLC is a biopharmaceutical enterprise dedicated to creating therapies for diabetes and various other medical conditions. The company utilizes its exclusive Arestat formulation technology platform to both cultivate its own range of specialized products (for diabetes and other ailments) and collaborate with pharmaceutical and biotechnology partners to refine and enhance existing therapeutic formulations. Its pipeline includes AT247, an exceptionally fast-acting insulin aimed at individuals with Type I and Type II diabetes, and AT278, a highly concentrated rapid-acting insulin formulation engineered to hasten insulin absorption following injection. Established in 2007, the company's main office is situated in Little Chesterford, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -8.97% | -8.97% | -18.01% | +51.72% | -74.12% | -72.73% | -72.73% | -72.73% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-66.1% Q4'25: -110.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+105.4% ★ Q4'25: +164.0% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-262.6% Q4'25: +397.2% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-268.5% Q4'25: +715.6% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-1,022.5% Q4'25: -1,907.0% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+17.9% Q4'25: +28.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q4'25: -0.01× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
1.16M
est: 1.16M (-0.2%)
|
2.40M
est: 2.40M (+0.2%)
|
4.57M
est: 4.90M (-6.7%)
|
5.05M
est: 5.10M (-0.9%)
|
1.71M
est: 3.10M (-44.7%)
|
900.0K
878.0K – 922.0K
-71.0% YoY
|
1.05M
1.04M – 1.06M
+16.7% YoY
|
| EBITDA |
-6.27M
est: -1.16M (-440.3%)
|
-10.06M
est: -2.40M (-319.5%)
|
-8.39M
est: -4.90M (-71.3%)
|
-10.15M
est: -5.10M (-99.0%)
|
-4.39M
est: -3.10M (-41.5%)
|
-900.0K
-922.0K – -878.0K
+71.0% YoY
|
-1.05M
-1.06M – -1.04M
-16.7% YoY
|
| EBIT |
-6.44M
est: -1.16M (-455.0%)
|
-10.40M
est: -2.40M (-333.8%)
|
-8.89M
est: -4.90M (-81.4%)
|
-10.60M
est: -5.10M (-107.8%)
|
-4.60M
est: -3.10M (-48.5%)
|
-900.0K
-922.0K – -878.0K
+71.0% YoY
|
-1.05M
-1.06M – -1.04M
-16.7% YoY
|
| Net Income |
-6.17M
est: -8.69M (+29.0%)
|
-9.26M
est: -9.42M (+1.7%)
|
-8.55M
est: -11.16M (+23.3%)
|
-10.24M
est: -10.24M (+0.0%)
|
664.0K
est: -526.5K (+226.1%)
|
-6.12M
-6.30M – -5.93M
-1,061.8% YoY
|
-4.45M
-4.51M – -4.38M
+27.3% YoY
|
| SGA |
2.39M
est: 1.97M (+21.0%)
|
5.55M
est: 4.08M (+36.0%)
|
8.91M
est: 9.08M (-1.9%)
|
6.18M
est: 9.46M (-34.7%)
|
2.96M
est: 5.75M (-48.5%)
|
1.67M
1.63M – 1.71M
-71.0% YoY
|
1.95M
1.93M – 1.97M
+16.7% YoY
|
| EPS |
-0.27
est: -0.26 (-3.8%)
|
-0.32
est: -0.33 (+1.6%)
|
-0.28
est: -0.28 (+1.0%)
|
-0.31
est: -0.27 (-13.5%)
|
0.02
est: -0.01 (+231.8%)
|
-0.16
-0.16 – -0.15
-1,061.8% YoY
|
-0.11
-0.11 – -0.11
+27.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 4/5 | 5/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 4/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 2/5 | 1/5 | 3/5 | 5/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sarah Jennifer Howell | Chief Executive Officer & Executive Director | 520.0K | — |
| David J. Ellam | Chief Financial Officer & Executive Director | 321.4K | male |
| David Gerring | Chief Development Officer | — | male |
| Jan Jezek | Chief Scientific Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AREC.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
